Mounjaro vs Zepbound: Same Drug, Different Label

The tirzepatide version of the Ozempic-vs-Wegovy confusion is Mounjaro versus Zepbound. Once again, these are not two different drugs. Both are tirzepatide, both are made by Eli Lilly, and the medication in the injector is the same. The split is entirely about which condition each product is approved to treat.

Surgery, hospital, doctor — illustrating Mounjaro vs Zepbound: Same Drug, Different Label

One molecule, two approvals

Tirzepatide is a dual agonist — it activates both the GLP-1 and the GIP receptor, two incretin pathways. Hitting both is the leading explanation for why tirzepatide tends to produce larger weight loss than GLP-1-only drugs. That mechanism is identical in both products.

Mounjaro was approved in 2022 for type 2 diabetes, dosed weekly and titrated across a ladder from 2.5 mg up to 15 mg. Its diabetes evidence comes from the SURPASS trial program.
Zepbound was approved in 2023 for chronic weight management in adults with obesity or overweight with a related condition, using the same 2.5-to-15 mg ladder. Its weight-loss evidence comes from the SURMOUNT program — SURMOUNT-1 reported roughly 21% average weight loss at the 15 mg dose. In 2024, Zepbound also gained an indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial.

Side by side

	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly	Eli Lilly
FDA approval	2022	2023
Primary indication	Type 2 diabetes	Chronic weight management
Additional indication	—	Obstructive sleep apnea (with obesity)
Dose range	2.5–15 mg / week	2.5–15 mg / week
Route	Weekly subcutaneous injection	Weekly subcutaneous injection

Notice that, unlike Ozempic and Wegovy, the dose ladders here are the same. There’s no higher-dose obesity version — the difference is purely which label the prescription is written under.

Because Mounjaro and Zepbound share the identical molecule and dose range, the weight-loss potential is the same. What changes is the approved indication, which drives coverage and eligibility.

Mistletoe, parasitic, medicinal plant — illustrating Mounjaro vs Zepbound: Same Drug, Different Label

Why the two labels exist at all

If the drug and the doses are identical, the natural question is why bother with two products. The answer is regulatory and commercial. FDA approvals are indication-specific, so a drug studied and cleared for diabetes needs a separate approval — and separate labeling, trials, and often separate pricing and coverage — to be marketed for obesity. Keeping the brands distinct lets the manufacturer, insurers, and pharmacies track which use a given prescription is for. It also means your insurance may cover one and not the other depending on your diagnosis, even though the vial contents don’t change.

Medical emergency, first aid, fire drill — illustrating Mounjaro vs Zepbound: Same Drug, Different Label

Mounjaro/Zepbound vs Ozempic/Wegovy

Since people usually arrive at this comparison while also weighing the semaglutide products, the one durable point is this: tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist and, in the head-to-head SURMOUNT-5 trial, produced more weight loss than semaglutide (Wegovy). Semaglutide, in turn, carries a longer cardiovascular-outcomes record. “More weight loss on average” and “best for a specific person” are not the same claim — tolerability, cost, access, and clinical history all matter.

The takeaway

Mounjaro and Zepbound are the same tirzepatide, at the same doses, cleared for different conditions — diabetes versus weight management and sleep apnea. There is no pharmacological reason to prefer one for weight loss over the other; the deciding factors are your diagnosis, what your prescriber is treating, and what your plan will cover. That’s a decision for a clinician, not a brand preference.